Injectable Naltrexone Tools & Resources

Injectable Naltrexone Administrative Cost Estimator

Medications for opioid use disorder (MOUD), including injectable naltrexone (IN), are part of evidence-based OUD treatments. When authorized to administer non-vaccination injections, pharmacists can increase IN accessibility. However, inadequate reimbursement for pharmacist-administered IN can hinder widespread adoption. This tool, developed in conjunction with community pharmacies in Wisconsin, is designed to provide an estimate of the total costs and time associated with community pharmacist administered IN for new and returning clients.

Injectable Naltrexone Administrative Cost Estimator

Brochures

Injectable Naltrexone Brochure

The Ford Research Group developed an Injectable Naltrexone Brochure for use by any community pharmacist as a tool for marketing their injectable naltrexone service to providers and clinics. The brochure is provided as a downloadable Word document so pharmacies can customize it by inserting their pharmacy logo and contact information.

Injectable Naltrexone Brochure

Naloxone Brochures

The Ford Research Group developed  Naloxone Brochures for each of the types of naloxone administration (intranasal spray, intranasal, and intramuscular) so that they can serve as an educational resource for community pharmacists when dispensing naloxone to patients.

Naloxone Brochures

Wisconsin Association of Treatment Court Professionals (WATCP) Related Resources

WATCP Handout

Exploring the role of community pharmacist-provided injectable naltrexone (Vivitrol®) for treatment court participants (PDF)

WATCP and Community Pharmacists Webinar

Click on the video below to view a panel discussion among community pharmacists in WI who offer injectable naltrexone and Wisconsin Association of Treatment Court Professionals (WATCP) affiliated Treatment Court Coordinators.

Interviews with Pharmacists and Medical Providers

Interviews with Pharmacists

We interviewed two community pharmacists who provide injectable naltrexone to learn more about their service.

An interview with Mike Kuckes, RPh, of Hometown Pharmacy in Monroe, WI.

An interview with John Lemke, PharmD, of Streu’s Pharmacy in Green Bay, WI.

Interviews with Medical Providers

We  interviewed medical providers, including physicians, physician assistants, and nurse practitioners, to elicit information about pharmacist-provided injectable naltrexone for opioid use disorder. Click on the links below to view clips from these interviews.

Immediate Reactions [Physicians]

Immediate Reactions [Nurse Practitioners]

Effective Communication Strategies [Physicians]

Information Sheet [Nurse Practitioners]

Communication & Outreach [Nurse Practitioners]

Information General [Nurse Practitioners]

Information Benefits [Nurse Practitioners]

Information to Make a Referral [Physicians]

Information Post Injection [Physicians]

Information Post Injection [Nurse Practitioners]

Information Returning Patients [Nurse Practitioners]

Pharmacy Forms

The attached forms have been provided by Omro Pharmacy (Vivitrol Treatment Informed Consent Form) and Smith Pharmacy (Vivitrol Pre-Injection Verification Questions for Patients) as part of their documentation process when providing injectable naltrexone to individuals in the community. Feel free to modify these forms for your own purpose.

  • Omro Pharmacy Form (Word)
  • Smith Pharmacy Form (Word)
ISPW 2024 Presentation

Dr. Jay Ford presented at the International Social Pharmacy Workshop (ISPW) conference on Wednesday, July 10, 2024.

  • Designing for Dissemination and Sustainability: Stakeholder Engagement to Develop Community Pharmacy Educational Materials (PDF)

 

Featured Publications

Gilson AM, Gassman M, Mott DA, Bryan G, Gicquelais R, Ford JH 2nd. Benefit of Pharmacy-Provided Naltrexone Injection Services for APNPs Offering Medication Treatment for Opioid Use Disorder: Resources from a Pharmacy/Nursing Collaborative. The Wisconsin Nurse. June 2022: p. 14. (PDF)

Ford JH 2nd, Gilson AM, Bryan G, Augustine C, Gassman M, Mott DA. Community pharmacy-based injectable naltrexone service delivery models and best practices. Res Social Adm Pharm. 2021;17(7):1332-1341. https://doi.org/10.1016/j.sapharm.2020.10.004

Ford JH 2nd, Gilson A, Mott DA. Systematic Analysis of the Service Process and the Legislative and Regulatory Environment for a Pharmacist-Provided Naltrexone Injection Service in Wisconsin. Pharmacy (Basel). 2019;7(2):59. Published 2019 Jun 12. https://doi.org/10.3390/pharmacy7020059

All References

The following references are applicable to this website:

  1. Center for Drug Evaluation Research, Food and Drug Administration. The Voice of the Patient A series of reports from the U.S. Food and Drug Administration’s (FDA’s) Patient-Focused Drug Development Initiative. Food and Drug Administration. URL: https://www.fda.gov/media/124391/download#:~:text=In%202016%2C%20an%20estimated%202.1,to%20significant%20impairment%20or%20distress
  2. Abraham AJ, Andrews CM, Yingling ME, Shannon J. Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees. Health Serv Res. 2018;53(1):389–404. https://onlinelibrary.wiley.com/doi/10.1111/1475-6773.12686.
  3. Skolnick P. The opioid epidemic: crisis and solutions. Annu Rev Pharmacol Toxicol. 2018;58:143–159. https://www.annualreviews.org/doi/10.1146/annurev-pharmtox-010617-052534
  4. U.S. Department of Health and Human Services (HHS). Office of the Surgeon General, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington (DC): HHS; November 2016. URL: https://addiction.surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf
  5. Substance Abuse and Mental Health Services A. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. Rockville, MD. HHS Publication No. PEP19-5068, NSDUH Series H-54; 2019. Accessed from: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf
  6. National Academies of Sciences, Engineering, and medicine; health and medicine Division; board on health Sciences Policy; committee on Pain management and regulatory Strategies to address prescription opioid abuse, 4, Trends in Opioid Use, Harms, and Treatment. In: Phillips JK, Ford MA, Bonnie RJ, eds. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington (DC): National Academies Press (US); 2017 Jul 13. Accessed from: https://www.ncbi.nlm.nih.gov/books/NBK458661/
  7. Renewal of the determination that a public health emergency exists nationwide as the result of the opioid crisis. Accessed from: https://www.phe.gov/emergency/news/healthactions/phe/Pages/opioid-16oct2019.aspx
  8. Compton WM, Jones CM, Baldwin GT. Relationship between Nonmedical Prescription-Opioid Use and Heroin Use. N Engl J Med. 2016;374(2):154-163. doi:10.1056/NEJMra1508490
  9. Weiss A, Elixhauser A, Barrett M, Steiner C, Bailey M, O’Malley L. Opioid-related inpatient stays and emergency department visits by state, 2009-2014. Healthcare Cost and Utilization Project. Statistical Brief# 219. January 2017. Accessed from: https://hcup-us.ahrq.gov/reports/statbriefs/sb219-Opioid-Hospital-Stays-ED-Visits-by-State.jsp
  10. Wurcel AG, Anderson JE, Chui KK, et al. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. Open Forum Infect Dis. 2016;3(3):ofw157. Published 2016 Jul 26. doi:10.1093/ofid/ofw157
  11. Peterson C, Xu L, Mikosz CA, Florence C, Mack KA. US hospital discharges documenting patient opioid use disorder without opioid overdose or treatment services, 2011-2015. J Subst Abuse Treat. 2018;92:35-39. https://doi.org/10.1016/j.jsat.2018.06.008
  12. Centers for Disease Control and Prevention. 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States. Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published August 31, 2018. Accessed from https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf
  13. Vivolo-Kantor AM, Seth P, Gladden RM, et al. Vital Signs: Trends in Emergency Department Visits for Suspected Opioid Overdoses – United States, July 2016-September 2017. MMWR Morb Mortal Wkly Rep. 2018;67(9):279-285. Published 2018 Mar 9. doi:10.15585/mmwr.mm6709e1
  14. Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The Burden of Opioid-Related Mortality in the United States. JAMA Netw Open. 2018;1(2):e180217. Published 2018 Jun 1. doi:10.1001/jamanetworkopen.2018.0217
  15. 2017 Drug Overdose Death Rates. 2019. Accessed from: https://www.cdc.gov/drugoverdose/deaths/2017.html
  16. 2016-2017 Drug Overdose Death Rate Increases. 2019. Accessed from: https://www.cdc.gov/drugoverdose/deaths/2016-2017-increase.html.
  17. Substance Abuse and Mental Health Services Administration. (2017). Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/
  18. Woolf SH, Aron L. Failing health of the United States. BMJ. 2018;360:k496. Published 2018 Feb 7. doi:10.1136/bmj.k496
  19. Brundage SC, Levine C. The Ripple Effect: The Impact of the Opioid Epidemic on Children and Families. United Hospital Fund and Milbank Memorial Fund. URL: https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101777609-pdf
  20. Substance Abuse and Mental Health Services Administration. Medication-Assisted Treatment. Last Updated: 01/04/2021. Accessed from: https://www.samhsa.gov/medication-assisted-treatment
  21. Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2021. Access from: https://store.samhsa.gov/
  22. Cousins G, Boland F, Courtney B, Barry J, Lyons S, Fahey T. Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study. Addiction. 2016;111(1):73-82. doi:10.1111/add.13087
  23. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. Published 2017 Apr 26. doi:10.1136/bmj.j1550
  24. Schuckit MA. Treatment of Opioid-Use Disorders. N Engl J Med. 2016;375(4):357-368. doi:10.1056/NEJMra1604339
  25. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–145. https://www.acpjournals.org/journal/aim
  26. Volkow ND, Wargo EM. Overdose Prevention Through Medical Treatment of Opioid Use Disorders. Ann Intern Med. 2018;169(3):190-192. doi:10.7326/M18-1397
  27. Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–96. https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(16)30413-5/fulltext
  28. Cobaugh DJ, Gainor C, Gaston CL, et al. The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems. Am J Health Syst Pharm. 2014;71(18):1539-1554. doi:10.2146/ajhp140157
  29. Compton WM, Jones CM, Stein JB, Wargo EM. Promising roles for pharmacists in addressing the U.S. opioid crisis. Res Social Adm Pharm. 2019;15(8):910-916. doi:10.1016/j.sapharm.2017.12.009
  30. Reynolds V, Causey H, McKee J, Reinstein V, Muzyk A. The Role of Pharmacists in the Opioid Epidemic: An Examination of Pharmacist-Focused Initiatives Across the United States and North Carolina. N C Med J. 2017;78(3):202-205. doi:10.18043/ncm.78.3.202
  31. Ullrich F, Salako A, Mueller K. Issues Confronting Rural Pharmacies after a Decade of Medicare Part D. Rural Policy Brief. 2017;(2017 3):1-5. Published 2017 Apr 1.
  32. National Association of Chain Drug Stores 2011-2012 chain pharmacy industry profile. Alexandria, VA: National Association of Chain Drug Stores;2011.
  33. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513. doi:10.1016/S0140-6736(11)60358-9
  34. Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973-981. doi:10.1001/archgenpsychiatry.2012.1a
  35. Lee JD, Friedmann PD, Kinlock TW, et al. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016;374(13):1232-1242. doi:10.1056/NEJMoa1505409
  36. Robertson AG, Easter MM, Lin HJ, Frisman LK, Swanson JW, Swartz MS. Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness. J Subst Abuse Treat. 2018;86:17-25. doi:10.1016/j.jsat.2017.12.003
  37. Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188-1209. doi:10.1111/add.14180
  38. Saxon AJ, Akerman SC, Liu CC, Sullivan MA, Silverman BL, Vocci FJ. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol’s Cost and Treatment Outcomes Registry. Addiction. 2018;113(8):1477-1487. doi:10.1111/add.14199
  39. Ford JH 2nd, Gilson AM, Bryan G, Augustine C, Gassman M, Mott DA. Community pharmacy-based injectable naltrexone service delivery models and best practices. Res Social Adm Pharm. 2021;17(7):1332-1341. doi:10.1016/j.sapharm.2020.10.004